Regenxbio (NASDAQ:RGNX) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Risk & Volatility
Regenxbio has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Regenxbio and Cidara Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Regenxbio currently has a consensus price target of $63.40, indicating a potential upside of 112.82%. Cidara Therapeutics has a consensus price target of $6.65, indicating a potential upside of 105.88%. Given Regenxbio’s higher possible upside, analysts clearly believe Regenxbio is more favorable than Cidara Therapeutics.
This table compares Regenxbio and Cidara Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
77.5% of Regenxbio shares are owned by institutional investors. Comparatively, 58.6% of Cidara Therapeutics shares are owned by institutional investors. 14.1% of Regenxbio shares are owned by insiders. Comparatively, 6.8% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Regenxbio and Cidara Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Regenxbio||$35.23 million||31.57||-$94.73 million||($3.26)||-9.14|
|Cidara Therapeutics||$20.92 million||6.63||-$41.09 million||($1.41)||-2.29|
Cidara Therapeutics has lower revenue, but higher earnings than Regenxbio. Regenxbio is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regenxbio beats Cidara Therapeutics on 7 of the 13 factors compared between the two stocks.
Regenxbio Company Profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.